Quest Diagnostics Buys Genetic Testing Company
Quest Diagnostics (NYSE: DGX) broadened its scope in genetics and rare diseases with the January 22 acquisition of Blueprint Genetics, based in Helsinki, Finland. Founded in 2012, the target now serves customers in more than 70 countries. Financial terms of the all-cash equity transaction were not disclosed. Blueprint is a leading specialty genetic testing company with deep expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics. It provides 3,900 targeted single gene and more than 200 panel tests spanning 14 medical specialties. Its growth comes largely from its proprietary guideline-supported methods of gene variant interpretation... Read More »
Laboratories, MRI and Dialysis Deals Fared Just Fine in Q4
A few final deals are still rolling in for the last month of 2019, and it seems like the Laboratories, MRI & Dialysis sector fared well. Deal count was down from Q4 2018, 14 this quarter compared to a total of 19 in Q4 2019. However, dollar volume is higher, buoyed by a few large transactions. Cinven and Astorg, two private equity firms, teamed up for the largest transaction of the sector in Q4, purchasing LGC Group for roughly $3.88 billion, according to a report in Private Equity News. LGC provides a range of measurement tools, proficiency testing schemes, supply chain assurance standards, and specialty genomics reagents to the life sciences industry in over 22 countries. KKR (NYSE:... Read More »
2019’s Biggest Healthcare Deals, by Sector
2020 has just begun, which means it’s time to look back at the healthcare M&A landscape of 2019. Just three days into the new year, nearly 1,780 deals are already on the books for 2019. More deals will turn up as we search our many sources, but the number likely won’t top the record of 1,900-plus set in 2018. Thanks to the multi-billion-dollar deals announced in the Biotech and Pharmaceutical sectors, 2019 will set a new spending record. Preliminary data show $399.1 billion was spent on healthcare acquisitions last year, about 20% higher than in 2018. We expect that number to rise as we go through the year and the 10Ks and quarterly reports come out. It’s possible the... Read More »
LGC Gets New Owners After Multi-Billion Deal
Cinven and Astorg have joined forces to purchase LGC Group from KKR (NYSE: KKR). The two global private equity firms spent $3.88 billion (£3 billion) for the firm, according to sources cited in Private Equity News. LGC provides a range of measurement tools, proficiency testing schemes, supply chain assurance standards, and specialty genomics reagents to the life sciences industry. According to our Deal Search Online database, this is the largest deal in the Laboratories, MRI and Dialysis sector, based on disclosed prices in 2019. This deal ends a four-year partnership that started in December 2015 when KKR acquired LGC for $989 million. At the time, LGC was a portfolio company of... Read More »
Phenomics Health Adds Clinical Assessment Capabilities
Making sure patients with multiple chronic conditions aren’t over- or under-dosed with medications can be a fraught process. Phenomics Health, based in Ann Arbor, Michigan, has been working on the genomics side of the problem. Its recent acquisition of Precera Bioscience’s patented portfolio of pharmacometabolomic technology adds capabilities to provide a more complete view of patients’ potential and actual response to medications than is currently available. Phenomics Health is a bioinformatics platform-based precision medicine company that uses artificial intelligence and machine learning to translate advanced genetic, epigenetic, multi-omics and health data into novel... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
